| Date | Title | Description |
| 25.08.2026 | Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biophar... |
| 14.07.2026 | Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed By Utebzi Milestones And Royalties | Spero Therapeutics, a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates o... |
| 08.07.2026 | Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval for Segmented Production | First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing.
Demonstrated a unified quality system, strict risk assessment protocols, and compliance with rigorous regulatory requiremen... |
| 30.06.2026 | Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China | SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 25.06.2026 | Ollin Biosciences Raises $330 Million Series B To Advance OLN324 | Ollin Biosciences announced that it raised an oversubscribed $330 million Series B financing round. The round was co-led by new investor TCGX and founding investor ARCH Venture Partners. Participants included a16z Bio+Health, Blackstone Mul... |
| 22.06.2026 | Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma | SAN FRANCISCO and SUZHOU, China, June 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 08.06.2026 | 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline | SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 04.06.2026 | World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an... | SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 01.06.2026 | 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC | IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confi... |
| 01.06.2026 | 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy... | After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC
IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant... |
| 29.05.2026 | Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion | The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates.
Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but ... |
| 29.05.2026 | Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agre... |
| 29.05.2026 | Innovent Biologics: Up To $10.5 Billion Oncology Collaboration With Pfizer | Innovent Biologics announced a global strategic licensing and collaboration agreement with Pfizer focused on the research and development of 12 early-stage and de novo oncology programs, creating one of the largest oncology partnerships ann... |
| 19.05.2026 | Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences | SAN FRANCISCO and SUZHOU, China, May 19, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 19.05.2026 | Forlong Biotechnology: RMB 120 Million Series Pre-B Financing Raised To Advance Cytokine Therapy Pipeline | Forlong Biotechnology, a clinical-stage biotech company focused on developing cytokine therapies for patients with severe unmet medical needs, announced the completion of an RMB 120 million, approximately $17.5 million, Series Pre-B financi... |
| 13.05.2026 | Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions | SAN FRANCISCO and SUZHOU, China, May 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 22.04.2026 | Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, April 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 31.03.2026 | Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edem... | OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab
New anatomic data demonstrates OLN... |
| 26.03.2026 | Innovent Announces 2025 Annual Results and Business Updates | From China Leadership to Global Premier:
Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization
SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801)... |
| 24.03.2026 | The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China | 73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W.
SAN FRANCISCO and SUZHOU, China, March 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc... |
| 23.03.2026 | Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study | SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 02.03.2026 | Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 13.02.2026 | Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer | SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for th... |
| 11.02.2026 | Eli Lilly Secures Future with Orna Therapeutics Acquisition | Eli Lilly acquired Orna Therapeutics. The deal totals up to $2.4 billion. This secures groundbreaking circular RNA technology. Orna pioneers *in vivo* cell engineering. Their platform allows the body to generate therapies internally. This b... |
| 09.02.2026 | Фармкомпания Eli Lilly покупает американскую биотех-компанию Orna Therapeutics за $2,4 млрд | Американская фармацевтическая компания Eli Lilly (LLY.N) согласилась купить биотехнологическую компанию Orna Therapeutics за $2,4 млрд наличными, получив доступ к технологии, которая позволяет использовать собственные клетки пациентов для с... |
| 08.02.2026 | Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology | SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
| 27.01.2026 | Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma | SAN FRANCISCO and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 09.01.2026 | Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema an... | SAN FRANCISCO and SUZHOU, China, Jan. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
| 26.12.2025 | China Greenlights World’s First Dual-Immunotherapy for Colon Cancer Ahead of Surgery | (Yicai) Dec. 26 -- China's top drug regulator has approved Chinese pharmaceutical firm Innovent Biologics’ cancer drug Daboxin® (Ipilimumab N01 Injection) for use in combination with another monoclonal antibody as a pre-surgery immunotherap... |
| 25.12.2025 | China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval | TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MS... |
| 19.12.2025 | China puts down marker in diabetes, weight-loss drug research | Two phase III clinical studies of a China-developed weight-loss and diabetes drug have been published in Nature, representing a milestone for China's growing presence in global metabolic disease research.
The studies evaluated the impact of... |
| 18.12.2025 | Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature | SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 12.12.2025 | Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity | After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly s... |
| 10.12.2025 | Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody | SAN FRANCISCO and SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 09.12.2025 | Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis | SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 08.12.2025 | ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma | SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
| 07.12.2025 | Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List | SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 05.12.2025 | Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies | SAN FRANCISCO and SUZHOU, China, Dec. 5, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfac... |
| 25.11.2025 | Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population | SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 30.10.2025 | Innovent’s tie-up with Takeda tests investor faith in China’s biotech dream | Since early October, shares of China’s innovative drugmakers have trended downward. As investors quipped about the need for another major deal to restore confidence, one such event finally arrived.
On October 22, Innovent Biologics announce... |
| 29.10.2025 | BD Deals Emerge as New Favored Partnership Mode Among Chinese Biotech Startups | (Yicai) Oct. 29 -- Business development deals between Chinese biotech startups and overseas pharmaceutical firms are surging and evolving into more varied forms of partnership.
BD deals commonly involve startups licensing the regional or gl... |
| 27.10.2025 | Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 | The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group
DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP... |
| 19.09.2025 | Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes | SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 18.09.2025 | Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines fo... |
| 16.09.2025 | Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 | SAN FRANCISCO and SUZHOU, China, Sept. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 01.09.2025 | China Recap | Growth and strain | China Recap is a weekly roundup tracking Chinese companies expanding abroad, covering market entries, funding rounds, product launches, and global partnerships.
China’s corporate globalization strategy is evolving fast. Industry giants are ... |
| 27.08.2025 | Innovent Announces 2025 Interim Results and Business Updates | Robust revenue growth and substantial profit improvement
Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation
SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 /PRNewswire/ -- Innovent Biologics, I... |
| 25.08.2025 | Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer | SAN FRANCISCO and SUZHOU, China, Aug. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality me... |
| 25.08.2025 | Harbour BioMed Appoints Yajie Li as Chief Medical Officer | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 19.08.2025 | Innogen bets on longer-lasting GLP-1 drugs to stand out in crowded field | On August 15, Innogen, a pharmaceutical company focused on glucagon-like peptide-1 (GLP-1) therapies, debuted on the Hong Kong Stock Exchange. The company’s shares surged as much as 300% intraday and closed up 200%, pushing its market capit... |
| 05.08.2025 | Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 | SAN FRANCISCO and SUZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 17.07.2025 | Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | SAN FRANCISCO and SUZHOU, China, July 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 07.07.2025 | Beijing Hospital Is First to Prescribe China-Made GLP-1 Weight-Loss Drug | (Yicai) July 7 -- A public hospital in Beijing has issued the first prescription for Mazdutide, the first glucagon-like peptide-1 weight-loss drug developed by a Chinese firm and approved for marketing in the country.
Ji Linong, a professor... |
| 30.06.2025 | Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms | SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 27.06.2025 | Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management | SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 24.06.2025 | Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 22.06.2025 | Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 22, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 16.06.2025 | Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China | SAN FRANCISCO and SUZHOU, China, June 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 13.06.2025 | Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 13, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 06.06.2025 | A New Dawn in Cancer Treatment: Innovent and HUTCHMED's Breakthrough in Renal Cell Carcinoma | In the world of oncology, every breakthrough feels like a beacon of hope. Recently, Innovent Biologics and HUTCHMED announced a significant milestone: the acceptance of their New Drug Application (NDA) in China for a combination therapy tar... |
| 05.06.2025 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma | SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 05.06.2025 | China hits milestone in weight-loss drug | A China-led research team recently published results of a phase III clinical trial on a novel obesity treatment in the prestigious New England Journal of Medicine (NEJM), marking a significant milestone in the country's growing global influ... |
| 05.06.2025 | Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer | SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
| 04.06.2025 | Innovent Biologics: Pioneering New Frontiers in Cancer Treatment | In the ever-evolving landscape of oncology, Innovent Biologics stands as a beacon of hope. The company recently showcased groundbreaking data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Their innovative approach... |
| 04.06.2025 | Innovent Biologics' IBI363: A New Dawn in Cancer Treatment | In the world of oncology, hope often flickers like a candle in the dark. But at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Innovent Biologics shone a bright light on the future of cancer treatment with its groundb... |
| 04.06.2025 | 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non... | SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 03.06.2025 | 2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors | SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 03.06.2025 | ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer | SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2025 | 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorecta... | SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 01.06.2025 | ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunothera... | SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of... |
| 29.05.2025 | Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Resp... | SAN FRANCISCO and SUZHOU, China, May 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 26.05.2025 | Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM) | SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 16.05.2025 | Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3) | SAN FRANCISCO and SUZHOU, China, May 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 07.05.2025 | The Future of Dermatology: Dermavon’s IPO and the Race for Skin Health Solutions | In the world of dermatology, change is a constant. As the sun sets on traditional treatments, a new dawn rises with innovative therapies. Dermavon Holdings, a spinoff from China Medical System (CMS), is stepping into the spotlight with its ... |
| 07.05.2025 | Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein f... | SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for th... |
| 06.05.2025 | Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 | SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for th... |
| 26.04.2025 | Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer | SAN FRANCISCO and SUZHOU,China, April 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 24.04.2025 | Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU,China, April 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 07.04.2025 | As Chinese Pharma Stocks Dive, Insiders Say Novel Drug Deals Remain Untouched by US Tariff Hike | (Yicai) April 7 -- The sharp selloff in Chinese pharmaceutical stocks was mainly due to market panic after the US jacked up the import tax on Chinese goods by more than expected, according to industry sources, who pointed out that innovativ... |
| 31.03.2025 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma | SAN FRANCISCO and SUZHOU, China, March 31, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 27.03.2025 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting | SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 26.03.2025 | Innovent Announces 2024 Annual Results and Business Updates | First-ever positive profit, entering a new era of growth and global innovation
SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that d... |
| 24.03.2025 | Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer | SAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 19.03.2025 | Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China | SAN FRANCISCO and SUZHOU, China, March 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 14.03.2025 | China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease | SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 03.03.2025 | Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma | SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 24.02.2025 | NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon C... | SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 17.02.2025 | Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer | SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 17.01.2025 | Innovent's Breakthrough in Pancreatic Cancer Treatment: A New Hope for Patients | In the relentless battle against pancreatic cancer, a new warrior has emerged. Innovent Biologics, a biopharmaceutical company, has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA)... |
| 17.01.2025 | Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference | Advancing into new stage of sustainable growth and global innovation
SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ... |
| 17.01.2025 | Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 16.01.2025 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer | SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 06.01.2025 | Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference | SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 03.01.2025 | Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration | SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 02.01.2025 | Innovent and Roche: A New Dawn in Cancer Treatment | In the world of biopharmaceuticals, partnerships can spark innovation. Innovent Biologics, a rising star in the industry, has joined forces with Roche, a titan in oncology. Their collaboration centers on IBI3009, a novel antibody drug conju... |
| 02.01.2025 | Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate | SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 27.12.2024 | Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference | ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily... |
| 20.12.2024 | Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration | SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |